Phase I/II Trial of MEK Inhibitor MEK162 in Patients With Relapsed and or Refractory Acute Myeloid Leukemia and Patients With Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Binimetinib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Novartis
- 25 Mar 2021 Status changed to discontinued due to slow accrual.
- 24 Oct 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.